Clinical trials
Refractory Acute Lymphoblastic Leukemia clinical trials
Below are recruiting refractory acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 167 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06179524RecruitingPhase 2
CAR-T-19 for CD19-positive B-ALL in children and young adults
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
TianjinAges Up to 25 years - NCT06307600RecruitingEarly Phase 1
CAR T-Cell Therapy for Relapsed or Refractory B-ALL
This trial tests a new CAR T-cell therapy (called RD06-03) for people whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or hasn't responded to other treatments. It aims to see if the therapy is safe and can help fight the leukemia.
Hefei, AnhuiAges 3–70 - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT06793241RecruitingEarly Phase 1
Donor CAR-T cells for B-cell leukemia
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07429461RecruitingEarly Phase 1
SYNCAR-100 for relapsed B-ALL
This trial tests a new CAR-T cell therapy called SYNCAR-100 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. If you qualify, you would receive an infusion of specially modified immune cells designed to attack and kill leukemia cells.
Hangzhou, ZhejiangAges 18–75 - NCT07403630Recruiting
Tumor chemogenomic profiler for cancer patients of all ages
This trial uses a new testing platform to analyze the genes and proteins in your tumor, aiming to find the most effective treatments for people with cancer that has come back, is not responding to treatment, or has spread. It is designed for both children and adults with any type of blood cancer or solid tumor.
Palermo, PalermoAges 1 year+ - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Sydney, New South WalesAges 1–30 - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT07361029RecruitingPhase 1
CAR T cell therapy for adults with returning B-cell leukemia
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Riyadh, Riyadh RegionAges 18–75 - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT06581081Recruiting
CAR-T therapy with or without stem cell transplant for B-cell leukemia
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
Beijing, Beijing MunicipalityAges 12–65 - NCT07300683RecruitingPhase 1
Modified immune cells for T-cell leukemia/lymphoma
This trial tests a new type of immunotherapy called anti-CCR9 CAR T cells for people whose T-cell leukemia or lymphoma has not responded to standard chemotherapy. The treatment uses your own immune cells that are modified in a lab to find and attack cancer cells that have a specific marker (CCR9) on their surface.
LondonAges Any age - NCT07258043Recruiting
Lower-dose chemotherapy for frail adults with leukemia
This trial tests whether a personalized, lower-dose chemotherapy plan can help adults with acute lymphoblastic leukemia (ALL) who are frail or have other health problems. It aims to improve survival by adjusting the dose to what each person can handle.
Mexico City, Mexico CityAges 18 years+ - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 for adults and teens with relapsed B-ALL
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
Duarte, CaliforniaAges 12 years+ - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06890065Recruiting
JY231 injection for relapsed B-cell lymphoma or leukemia
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
Zhengzhou, HenanAges 18–75
Hear when a new Refractory Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 167 recruiting refractory acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory B Acute Lymphoblastic Leukemia
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- T-cell Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.